Reading Paige’s Playbook For Cancer Diagnostics
Paige CEO Andy Moye talked to Medtech Insight about the company’s current offerings in the prostate and breast cancer markets, as well as its future ambitions and general strategy.
You may also be interested in...
The two tech companies – one software giant, the other focused on oncology – will work together on what will likely be the largest artificial intelligence model of its kind.
The company has raised €14m to develop its AI-based pathology software which will make diagnosing cancer faster and easier.
The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.